文献速递神经肿瘤

成人免疫肿瘤学:以既往失败启示未来

Adult immuno-oncology: using past failures to inform the future.
PubMed 文献 · Neuro Oncol · 2020-01-01

本文基于2019年首届Remission Summit的讨论,由临床、科研及患者倡导者共同回顾胶质母细胞瘤(GBM)免疫治疗早期试验的混合结果,分析既往失败原因与当前局限,并提出推进免疫治疗作为GBM治疗手段的最佳实践策略。

要点

  • GBM免疫治疗早期试验结果喜忧参半,需系统分析失败原因。
  • 多学科专家与患者倡导者共同讨论免疫治疗过去、现在与未来。
  • 利用已发表和未发表知识识别治疗失败原因并优化推进策略。

核心结论

  • GBM免疫治疗早期试验结果混合,需通过失败分析识别原因并制定最佳实践以推进该治疗模式。

研究设计与样本

  • 基于2019年首届Remission Summit的专家与患者倡导者讨论,综合已发表和未发表知识进行失败分析与策略提出。

主要发现

  • 免疫治疗涵盖免疫检查点抑制剂、嵌合抗原受体T细胞疗法、疫苗和溶瘤病毒等多种手段。
  • GBM免疫治疗早期试验结果喜忧参半。

临床怎么用

  • 利用当前知识识别GBM免疫治疗试验失败的可能原因,并采用提出的最佳实践推进免疫治疗。

局限性

  • 讨论基于专家意见和现有知识,未报告系统检索或定量分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In oncology, "immunotherapy" is a broad term encompassing multiple means of utilizing the patient's immune system to combat malignancy. Prominent among these are immune checkpoint inhibitors, cellular therapies including chimeric antigen receptor T-cell therapy, vaccines, and oncolytic viruses. Immunotherapy for glioblastoma (GBM) has had mixed results in early trials. In this context, the past, present, and future of immune oncology for the treatment of GBM was discussed by clinical, research, and thought leaders as well as patient advocates at the first annual Remission Summit in 2019. The goal was to use current knowledge (published and unpublished) to identify possible causes of treatment failures and the best strategies to advance immunotherapy as a treatment modality for patients with GBM. The discussion focuses on past failures, current limitations, failure analyses, and proposed best practices moving forward.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Rahman M, Sawyer WG, Lindhorst S, et al. Adult immuno-oncology: using past failures to inform the future. Neuro Oncol. 2020. PMID: 32391559. doi:10.1093/neuonc/noaa116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。